Estamos realizando la búsqueda. Por favor, espere...
1575
37
170
28863
4397
2595
347
362
Abstract: We aimed to assess the ecacy of biologic therapy in refractory non-Multiple Sclerosis (MS) Optic Neuritis (ON), a condition more infrequent, chronic and severe than MS ON. This was an open-label multicenter study of patients with non-MS ON refractory to systemic corticosteroids and at least one conventional immunosuppressive drug. The main outcomes were Best Corrected Visual Acuity (BCVA) and both Macular Thickness (MT) and Retinal Nerve Fiber Layer (RNFL) using Optical Coherence Tomography (OCT). These outcome variables were assessed at baseline, 1 week, and 1, 3, 6 and 12 months after biologic therapy initiation. Remission was defined as the absence of ON symptoms and signs that lasted longer than 24 h, with or without an associated new lesion on magnetic resonance imaging with gadolinium contrast agents for at least 3 months. We studied 19 patients (11 women/8 men; mean age, 34.8 13.9 years). The underlying diseases were Bechet?s disease (n = 5), neuromyelitis optica (n = 3), systemic lupus erythematosus (n = 2), sarcoidosis (n = 1), relapsing polychondritis (n = 1) and anti-neutrophil cytoplasmic antibody -associated vasculitis (n = 1). It was idiopathic in 6 patients. The first biologic agent used in each patient was: adalimumab (n = 6), rituximab (n = 6), infliximab (n = 5) and tocilizumab (n = 2). A second immunosuppressive drug was simultaneously used in 11 patients: methotrexate (n = 11), azathioprine (n = 2), mycophenolate mofetil (n = 1) and hydroxychloroquine (n = 1). Improvement of the main outcomes was observed after 1 year of therapy when compared with baseline data: mean SD BCVA (0.8 0.3 LogMAR vs. 0.6 0.3 LogMAR; p = 0.03), mean SD RNFL (190.5 175.4 m vs. 183.4 139.5 m; p = 0.02), mean SD MT (270.7 23.2 m vs. 369.6 137.4 m; p = 0.03). Besides, the median (IQR) prednisone-dose was also reduced from 40 (10?61.5) mg/day at baseline to. 2.5 (0?5) mg/day after one year of follow-up; p = 0.001. After a mean SD follow-up of 35 months, 15 patients (78.9%) achieved ocular remission, and 2 (10.5%) experienced severe adverse events. Biologic therapy is eective in patients with refractory non-MS ON.
Fuente: Journal of clinical medicine 2020, 9, 2608
Editorial: MDPI
Año de publicación: 2020
Nº de páginas: 13
Tipo de publicación: Artículo de Revista
DOI: 10.3390/jcm9082608
ISSN: 2077-0383
Url de la publicación: https://doi.org/10.3390/jcm9082608
Consultar en UCrea Leer publicación
ALBA HERRERO-MORANT
CARMEN ÁLVAREZ-REGUERA
JOSÉ L. MARTÍN-VARILLAS
VANESA CALVO-RÍO
ALFONSO CASADO
DIANA PRIETO-PEÑA
BELÉN ATIENZA-MATEO
OLGA MAIZ-ALONSO
ANA BLANCO
ESTHER VICENTE
ÍÑIGO RÚA-FIGUEROA
LAURA CÁCERES
JOSÉ L. GARCÍA-SERRANO
JOSÉ LUIS CALLEJAS-RUBIO
JOSE LUIS HERNANDEZ HERNANDEZ
MIGUEL ANGEL GONZALEZ-GAY MANTECON
RICARDO BLANCO ALONSO
Volver